Is Actinium Pharmaceuticals Stock a Good Investment?
Actinium Pharmaceuticals Investment Advice | ATNM |
- Examine Actinium Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Actinium Pharmaceuticals' leadership team and their track record. Good management can help Actinium Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Actinium Pharmaceuticals' business and its evolving consumer preferences.
- Compare Actinium Pharmaceuticals' performance and market position to its competitors. Analyze how Actinium Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Actinium Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Actinium Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Actinium Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Actinium Pharmaceuticals is a good investment.
Sell | Buy |
Hold
Market Performance | Modest | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Actinium Pharmaceuticals Stock
Researching Actinium Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 30.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.22. Some equities with similar Price to Book (P/B) outperform the market in the long run. Actinium Pharmaceuticals recorded a loss per share of 1.39. The entity last dividend was issued on the 11th of August 2020. The firm had 1:30 split on the 11th of August 2020.
To determine if Actinium Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Actinium Pharmaceuticals' research are outlined below:
| Actinium Pharmaceuticals is way too risky over 90 days horizon | |
| Actinium Pharmaceuticals may become a speculative penny stock | |
| Actinium Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 81 K. Net Loss for the year was (48.82 M) with profit before overhead, payroll, taxes, and interest of 81 K. | |
| Actinium Pharmaceuticals currently holds about 116.33 M in cash with (47.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.62, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Actinium Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Actinium Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Actinium Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 1st of April 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 1st of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Actinium Pharmaceuticals' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 49.29 M.Basic technical analysis of Actinium Stock
As of the 26th of March, Actinium Pharmaceuticals shows the Risk Adjusted Performance of 0.1207, downside deviation of 4.41, and Mean Deviation of 4.26. Actinium Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Actinium Pharmaceuticals variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Actinium Pharmaceuticals is priced correctly, providing market reflects its regular price of 1.87 per share. Please also double-check Actinium Pharmaceuticals total risk alpha, which is currently at 0.7752 to validate the company can sustain itself at a future point.Actinium Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Actinium Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Actinium Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Actinium Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Seth Sandesh over three weeks ago Acquisition by Seth Sandesh of 8125 shares of Actinium Pharmaceuticals at 0.6 subject to Rule 16b-3 | ||
Almenoff June Sherie over three months ago Insider Trading | ||
Nicholson, C. David over six months ago Acquisition by Nicholson, C. David of 70311 shares of Actinium Pharmaceuticals at 5.0 subject to Rule 16b-3 | ||
Mark Berger over six months ago Acquisition by Mark Berger of 400000 shares of Actinium Pharmaceuticals at 0.232 subject to Rule 16b-3 | ||
C Nicholson over a year ago Acquisition by C Nicholson of 70311 shares of Actinium Pharmaceuticals subject to Rule 16b-3 |
Actinium Pharmaceuticals' Outstanding Corporate Bonds
Actinium Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Actinium Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Actinium bonds can be classified according to their maturity, which is the date when Actinium Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| ACTAVIS FDG SCS Corp BondUS00507UAS06 | View | |
| ACTIVISION BLIZZARD INC Corp BondUS00507VAQ23 | View | |
| US00507VAP40 Corp BondUS00507VAP40 | View | |
| ACTIVISION BLIZZARD INC Corp BondUS00507VAM19 | View | |
| ACTIVISION BLIZZARD INC Corp BondUS00507VAK52 | View |
Understand Actinium Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Actinium Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1207 | |||
| Market Risk Adjusted Performance | 0.3679 | |||
| Mean Deviation | 4.26 | |||
| Semi Deviation | 3.71 | |||
| Downside Deviation | 4.41 | |||
| Coefficient Of Variation | 753.5 | |||
| Standard Deviation | 5.79 | |||
| Variance | 33.52 | |||
| Information Ratio | 0.1314 | |||
| Jensen Alpha | 0.7636 | |||
| Total Risk Alpha | 0.7752 | |||
| Sortino Ratio | 0.1727 | |||
| Treynor Ratio | 0.3579 | |||
| Maximum Drawdown | 23.22 | |||
| Value At Risk | (7.14) | |||
| Potential Upside | 14.29 | |||
| Downside Variance | 19.41 | |||
| Semi Variance | 13.77 | |||
| Expected Short fall | (6.18) | |||
| Skewness | 1.1 | |||
| Kurtosis | 1.45 |
| Risk Adjusted Performance | 0.1207 | |||
| Market Risk Adjusted Performance | 0.3679 | |||
| Mean Deviation | 4.26 | |||
| Semi Deviation | 3.71 | |||
| Downside Deviation | 4.41 | |||
| Coefficient Of Variation | 753.5 | |||
| Standard Deviation | 5.79 | |||
| Variance | 33.52 | |||
| Information Ratio | 0.1314 | |||
| Jensen Alpha | 0.7636 | |||
| Total Risk Alpha | 0.7752 | |||
| Sortino Ratio | 0.1727 | |||
| Treynor Ratio | 0.3579 | |||
| Maximum Drawdown | 23.22 | |||
| Value At Risk | (7.14) | |||
| Potential Upside | 14.29 | |||
| Downside Variance | 19.41 | |||
| Semi Variance | 13.77 | |||
| Expected Short fall | (6.18) | |||
| Skewness | 1.1 | |||
| Kurtosis | 1.45 |
Consider Actinium Pharmaceuticals' intraday indicators
Actinium Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Actinium Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Actinium Pharmaceuticals time-series forecasting models is one of many Actinium Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Actinium Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Actinium Stock media impact
Far too much social signal, news, headlines, and media speculation about Actinium Pharmaceuticals that are available to investors today. That information is available publicly through Actinium media outlets and privately through word of mouth or via Actinium internal channels. However, regardless of the origin, that massive amount of Actinium data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Actinium Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Actinium Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Actinium Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Actinium Pharmaceuticals alpha.
Actinium Pharmaceuticals Corporate Management
| Bernie PMP | Executive Management | Profile | |
| Qing Liang | VP Sciences | Profile | |
| Madhuri MD | Vice Therapy | Profile | |
| Lynn MBA | Chief Officer | Profile | |
| Paul Esq | Vice Counsel | Profile | |
| Jenny Hsieh | Chief Officer | Profile | |
| Dr MS | VP Operations | Profile |
Already Invested in Actinium Pharmaceuticals?
The danger of trading Actinium Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Actinium Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Actinium Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Actinium Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Actinium Pharmaceuticals is a strong investment it is important to analyze Actinium Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Actinium Pharmaceuticals' future performance. For an informed investment choice regarding Actinium Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Actinium Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Actinium Pharmaceuticals. If investors know Actinium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Actinium Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Actinium Pharmaceuticals is measured differently than its book value, which is the value of Actinium that is recorded on the company's balance sheet. Investors also form their own opinion of Actinium Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Actinium Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Actinium Pharmaceuticals' market value can be influenced by many factors that don't directly affect Actinium Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Actinium Pharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Actinium Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Actinium Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.